权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer

ProstAtak 治疗前列腺癌的临床和免疫学评价

基本信息

批准号：
8240108
负责人：
Estuardo Aguilar-Cordova
金额：
$ 191.76万
依托单位：
ADVANTAGENE, INC
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
起止时间：
2007-08-10 至 2013-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8240108
关键词：
Acute Adenovirus Vector Adjuvant Adverse effects Advisory Committees Affect American Cancer Society Androgens Antigen-Presenting Cells Applications Grants Biometry Biopsy Blood specimen CD8B1 gene Cancer Etiology Cancer Patient Castration Cessation of life Clinical Clinical Protocols Clinical Research Clinical Trials Design Conduct Clinical Trials Control Groups Development Diagnosis Discipline Disease Disease-Free Survival Distant Dose Enrollment Evaluation Failure Freedom Future Genes Grant HSV-Tk Gene Human Immune Immunologics Immunology Immunotherapy Inflammatory Response Institution Institutional Review Boards Lead Life Malignant Neoplasms Malignant neoplasm of prostate Measurable Measures Mediating Modeling Neoplasm Metastasis Operative Surgical Procedures Oral Outcome Pathologic Pathology Patients Performance Pharmaceutical Preparations Phase Phase II Clinical Trials Placebo Control Placebos Population Predisposition Prodrugs Property Prostate Prostate Cancer therapy Prostate-Specific Antigen Protocols documentation Quality of life Radiation Radiation Oncology Radiation therapy Randomized Randomized Controlled Trials Reagent Recombinant DNA Recurrence Research Design Research Methodology Resistance development Resources Risk Safety Site Staging Superantigens Surrogate Endpoint T cell response T-Lymphocyte TK Gene Technology Testing Therapeutic Toxic effect Tumor Antigens United States National Institutes of Health Urology Vaccines Work Writing base cancer recurrence cancer therapy cell killing chemotherapy clinical research site control trial cytotoxic deprivation design experience follow-up high risk implementation trial improved institutional biosafety committee meetings men neoplastic cell novel therapeutics outcome forecast palliative patient population phase 1 study phase 2 study pre-clinical prevent product development randomized placebo controlled trial randomized trial response standard care standard of care success tumor uptake working group

项目摘要

ABSTRACT The main objective of this project is to develop a new therapeutic to improve the outcome for patients with intermediate-risk prostate cancer. The indication is a first-line adjuvant to be combined with radiation therapy for prostate cancer. The desired outcomes are improved local control rate, decreased recurrence and improved disease-free survival. This grant will enable development and evaluation of ProstAtak", a product aimed at improving the outcome of prostate cancer patients, in a randomized Phase 2 clinical study. Prostate cancer is the second leading cause of cancer death in men in the US with approximately 30,000 deaths expected in 2006. Current therapies provide an excellent 5yr survival prognosis for the 230,000 new annual diagnoses. However, each year 60,000-100,000 men develop prostate cancer recurrence for which they receive surgical or pharmacologic castration, a life extending but non-curative therapy. Castration negatively impacts quality of life. Drugs that decrease recurrence of prostate cancer and do not diminish current success from standard therapies would be of great significance. ProstAtak" is a biologic drug composed of an adenoviral vector with the Herpes thymidine-kinase gene (AdV-tk) formulated for prostate delivery followed by an oral antiherpetic prodrug. When combined with standard surgery or radiation, ProstAtak" has been shown to generate a systemic vaccine effect through a technology termed gene mediated cytotoxic immunotherapy (GMCI"). AdV-tk, the principal component of ProstAtak", has an excellent safety profile with over 300 patient doses delivered in multiple Phase 1 studies, and a non-randomized Phase 2 study. Prostate cancer has shown susceptibility to ProstAtak" alone, and in the context of GMCI" with radiation. The purpose of this application is to support design, implementation and evaluation of a randomized Phase 2 controlled trial of ProstAtak" with radiation compared to placebo with radiation in localized intermediate-risk prostate cancer. A working group of urology, radiation therapy, pathology, immunology and biostatistics experts from top academic institutions has been assembled to collaborate in the development and conduct the proposed studies. A clinical protocol from this group has been prepared. The intermediate-risk group was selected based on positive results from the non-randomized study, the potential to differentiate outcomes in this patient population, and because standard treatment for this stage provides an opportunity to easily incorporate GMCI" without adding significant discomfort to the patients. The proposed trial will be the first to prospectively evaluate efficacy of AdV-tk in humans and, if successful, may lead to the first drug with early stage prostate cancer as its primary indication. A secondary objective is to prospectively evaluate surrogate end-points for early stage prostate cancer.

摘要